Recruiting
A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma
NCT05302284
- Conditions
- Carcinoma, Carcinoma, Transitional Cell, HER2-expressing, +4 more
- Locations
-
- Cancer Hospital Chinese Academy of Medical Sciences Beijing, Beijing Municipality, China
- Beijing Cancer Hospital Beijing, China